Postnatal fate of donor mesenchymal stem cells after transamniotic stem cell therapy in a healthy model
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Mar 2020 · 1 min read
In brief
In brief
Preclinical study tracking donor mesenchymal stem cells after intraamniotic injection in healthy rat fetuses found no detectable cells in neonatal tissues 16 days postnatally, despite confirmed viability at term. Findings support safety profile for clinical translation of transamniotic stem cell therapy.
Written by the GCMD Library team from the article.
Purpose
We sought to examine donor mesenchymal stem cell (MSC) fate after birth following transamniotic stem cell therapy (TRASCET) in a healthy model.
Methods
Lewis rat fetuses (n = 91) were divided into two groups based on the content of volume-matched intraamniotic injections performed on gestational day 17 (term = 21–22 days): either a suspension of amniotic fluid-derived MSCs (afMSCs) labeled with luciferase (n = 38) or acellular luciferase only (n = 53). Infused afMSCs consisted of syngeneic Lewis rat cells phenotyped by flow cytometry. Samples from 14 anatomical sites (heart, lung, brain, liver, spleen, pancreas, bowel, kidney, thyroid, skin, skeletal muscle, thymus, peripheral blood and bone marrow) from survivors were screened for luciferase activity 16 days after birth. Statistical analysis was by logistic regression and the Wald test (p 0.05). Donor afMSC viability was confirmed in term placentas.
Conclusions
Donor mesenchymal stem cells are not detectable in the neonate after intraamniotic injection in a normal syngeneic rodent model. This finding suggests that clinical trials of transamniotic stem cell therapy may be amenable to regulatory approval.
Level of evidence
N/A (animal and laboratory study).